MedTrace Logo

Clinical Study on the Safety and Immunogenicity of Specific Cancer Vaccines in Preventing Recurrence of Glioblastoma

NCT07520214 · Status: ENROLLING_BY_INVITATION · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2026-04-09

No results posted yet for this study

Summary

This study evaluates the safety and specific antitumor immune responses of mRNA vaccines GV-108 and GV-907 in IDH-wildtype glioblastoma patients.

Conditions

  • Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
  • Glioblastom WHO Grade 4

Interventions

BIOLOGICAL

mRNA vaccine: GV-907、GV-108

Eligible patients will receive intradermal injections of cancer vaccines

Sponsors & Collaborators

  • Beijing Neurosurgical Institute

    lead OTHER

Principal Investigators

  • Fusheng Liu, MD,PhD · Beijing Tiantan Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-10
Primary Completion
2027-12-31
Completion
2027-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07520214 on ClinicalTrials.gov